全文获取类型
收费全文 | 7703篇 |
免费 | 414篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 82篇 |
儿科学 | 195篇 |
妇产科学 | 196篇 |
基础医学 | 1103篇 |
口腔科学 | 326篇 |
临床医学 | 619篇 |
内科学 | 1346篇 |
皮肤病学 | 119篇 |
神经病学 | 792篇 |
特种医学 | 510篇 |
外科学 | 1133篇 |
综合类 | 37篇 |
一般理论 | 2篇 |
预防医学 | 399篇 |
眼科学 | 214篇 |
药学 | 536篇 |
中国医学 | 14篇 |
肿瘤学 | 538篇 |
出版年
2023年 | 43篇 |
2022年 | 117篇 |
2021年 | 207篇 |
2020年 | 148篇 |
2019年 | 172篇 |
2018年 | 186篇 |
2017年 | 172篇 |
2016年 | 230篇 |
2015年 | 257篇 |
2014年 | 316篇 |
2013年 | 465篇 |
2012年 | 601篇 |
2011年 | 591篇 |
2010年 | 355篇 |
2009年 | 310篇 |
2008年 | 510篇 |
2007年 | 500篇 |
2006年 | 445篇 |
2005年 | 430篇 |
2004年 | 360篇 |
2003年 | 358篇 |
2002年 | 337篇 |
2001年 | 70篇 |
2000年 | 49篇 |
1999年 | 60篇 |
1998年 | 54篇 |
1997年 | 43篇 |
1996年 | 56篇 |
1995年 | 53篇 |
1994年 | 42篇 |
1993年 | 30篇 |
1992年 | 38篇 |
1991年 | 26篇 |
1990年 | 17篇 |
1989年 | 22篇 |
1988年 | 21篇 |
1987年 | 31篇 |
1986年 | 28篇 |
1985年 | 36篇 |
1984年 | 29篇 |
1983年 | 20篇 |
1982年 | 28篇 |
1981年 | 18篇 |
1980年 | 18篇 |
1979年 | 14篇 |
1978年 | 15篇 |
1977年 | 16篇 |
1974年 | 18篇 |
1971年 | 14篇 |
1967年 | 17篇 |
排序方式: 共有8161条查询结果,搜索用时 15 毫秒
991.
992.
993.
Matej Orešič Tuulia Hyötyläinen Anna Kotronen Peddinti Gopalacharyulu Heli Nygren Johanna Arola Sandra Castillo Ismo Mattila Antti Hakkarainen Ronald J. H. Borra Miikka-Juhani Honka An Verrijken Sven Francque Patricia Iozzo Marja Leivonen Nabil Jaser Anne Juuti Thorkild I. A. Sørensen Pirjo Nuutila Luc Van Gaal Hannele Yki-Järvinen 《Diabetologia》2013,56(10):2266-2274
Aims/hypothesis
We examined whether analysis of lipids by ultra-performance liquid chromatography (UPLC) coupled to MS allows the development of a laboratory test for non-alcoholic fatty-liver disease (NAFLD), and how a lipid-profile biomarker compares with the prediction of NAFLD and liver-fat content based on routinely available clinical and laboratory data.Methods
We analysed the concentrations of molecular lipids by UPLC-MS in blood samples of 679 well-characterised individuals in whom liver-fat content was measured using proton magnetic resonance spectroscopy (1H-MRS) or liver biopsy. The participants were divided into biomarker-discovery (n?=?287) and validation (n?=?392) groups to build and validate the diagnostic models, respectively.Results
Individuals with NAFLD had increased triacylglycerols with low carbon number and double-bond content while lysophosphatidylcholines and ether phospholipids were diminished in those with NAFLD. A serum-lipid signature comprising three molecular lipids (‘lipid triplet’) was developed to estimate the percentage of liver fat. It had a sensitivity of 69.1% and specificity of 73.8% when applied for diagnosis of NAFLD in the validation series. The usefulness of the lipid triplet was demonstrated in a weight-loss intervention study.Conclusions/interpretation
The liver-fat-biomarker signature based on molecular lipids may provide a non-invasive tool to diagnose NAFLD, in addition to highlighting lipid molecular pathways involved in the disease. 相似文献994.
Ina Oehme Jan-Peter Linke Barbara C. B?ck Till Milde Marco Lodrini Bettina Hartenstein Inga Wiegand Christian Eckert Wilfried Roth Marcel Kool Sylvia Kaden Hermann-Josef Gr?ne Johannes H. Schulte Sven Lindner Anne Hamacher-Brady Nathan R. Brady Hedwig E. Deubzer Olaf Witt 《Proceedings of the National Academy of Sciences of the United States of America》2013,110(28):E2592-E2601
995.
Several guidelines recommended routine use of Disease Activity Score-28 (DAS28) to monitor disease and the response to treatment for rheumatoid arthritis (RA). In practice, it may be appropriate to use historical erythrocyte sedimentation rate (ESR) values in place of same-day ESR, thereby preventing unnecessary delay in adjusting intervention. We asked whether ESR blood samples taken up to 3 months prior to the clinic appointment were adequate to accurately assess RA disease activity using the DAS28. RA patients (N?=?66) who met the inclusion criteria were assessed at baseline and ESR obtained on the day of review to calculate the DAS28 and compared with the DAS28 derived from the latest previous ESR (mean interval, 38.6 days; range, 6–99 days). Limits of agreement (LoA) were used to assess the agreement between the DAS28 pairs. The mean age of the participants was 61.5 years (range, 20–83 years), with mean disease duration of 11.0 years (range, 0.1–40 years). Comparing the DAS28 using same-day ESR versus pre-recorded historical ESR showed a small statistical difference (mean, ?0.09; 95 %CI, ?0.1602 to ?0.017) in the DAS28 score. The calculated LoA (?0.66 and 0.48) demonstrated acceptable agreement between DAS28 pairs, with 7.6 % of patients residing outside the LoA, all of whom had a significant treatment change. Disease misclassification occurred in 9.1 % of patients who were close to disease activity boundaries. Our results indicate that differences in the DAS28 due to a previous or same-day ESR are unlikely to be clinically significant for RA patients with established disease. A decision to adjust treatment therefore may be confidently made for most patients using the most recent ESR for calculating the DAS28, provided there was no major change in treatment since the last ESR measurement. 相似文献
996.
Gilles Bonicelli Khadija Abdulkarim Morgane Mounier Peter Johansson Cdric Rossi Valrie Jooste Bjrn Andreasson Marc Maynadi Franois Girodon 《British journal of haematology》2013,160(2):251-254
Three hundred and twenty‐seven patients from two population‐based cohorts with an established diagnosis of polycythaemia vera were studied for prognostic risk factors for survival and leukaemia in a long‐term survey. The relative survival (RS) was 72% and 46% at 10 and 20 years respectively, from the time of diagnosis. Multivariate analysis identified age >70 years, white blood cell count >13 × 109/l and thrombo‐embolism at diagnosis as independent risk factors. Patients with two or three of these factors had a 10 year RS of 26%, compared with 59% and 84% in patients with one and no risk factors, respectively. Age and leucocyte count are the main predicting factors for survival in polycythaemia vera. 相似文献
997.
Eugen Retser Tanja Schied Boris V. Skryabin Thomas Vogl Janos M. Kanczler Nina Hamann Anja Niehoff Sven Hermann Michel Eisenbltter Lydia Wachsmuth Thomas Pap Peter L. E. M. van Lent Karin Loser Johannes Roth Frank Zaucke Stephan Ludwig Viktor Wixler 《Arthritis \u0026amp; Rheumatology》2013,65(9):2290-2300
998.
999.
1000.
Yi Hu Sven Hoffner Linlin Wu Qi Zhao Weili Jiang Biao Xu 《Antimicrobial agents and chemotherapy》2013,57(8):3857-3863
This study aimed to investigate the prevalence of resistance to second-line antituberculosis (anti-TB) drugs and its association with resistance-related mutations in Mycobacterium tuberculosis isolated in China. In the present study, we collected 380 isolates from a population-based study in China and tested the drug susceptibility to first- and selected second-line drugs. These results were compared with polymorphisms in the DNA sequences of genes associated with drug resistance and MIC values of the studied second-line drugs. Of 43 multidrug-resistant M. tuberculosis isolates, 13 showed resistance to fluoroquinolones or injectable second-line drugs (preextensively drug-resistant TB [pre-XDR-TB]), and 4 were resistant to both and thus defined as extensively drug-resistant TB (XDR-TB). Age and previous TB therapy, including use of second-line drugs, were two independent factors associated with increased resistance to both first- and second-line drugs. Molecular analysis identified the most frequent mutations in the resistance-associated genes: D94G in gyrA (29.1%) and A1401G in rrs (30.8%). Meanwhile, all 4 XDR-TB isolates had a mutation in gyrA, and 3 of them carried the A1401G mutation in rrs. Mutations in gyrA and rrs were associated with high-level resistance to fluoroquinolones and the second-line injectable drugs. In addition to the identification of resistance-associated mutations and development of a rapid molecular test to diagnose the second-line drug resistance, it should be a priority to strictly regulate the administration of second-line drugs to maintain their efficacy to treat multidrug-resistant TB. 相似文献